Type 2 Diabetes and its Treatment with Linagliptin are both Associated with Elevated Mortality in Bullous Pemphigoid

Leisti, Päivi; Pankakoski, Anna; Jokelainen, Jari; Huilaja, Laura; Panelius, Jaana; Tasanen, Kaisa; Varpuluoma, Outi (2024-09-04)
 
Avaa tiedosto
Lataukset: 

URL:
https://doi.org/10.2340/actadv.v104.40645

Leisti, Päivi
Pankakoski, Anna
Jokelainen, Jari
Huilaja, Laura
Panelius, Jaana
Tasanen, Kaisa
Varpuluoma, Outi
Medical Journals Sweden
04.09.2024

Leisti, P., Pankakoski, A., Jokelainen, J., Huilaja, L., Panelius, J., Tasanen, K., & Varpuluoma, O. (2024). Type 2 Diabetes and its Treatment with Linagliptin are both Associated with Elevated Mortality in Bullous Pemphigoid. Acta Dermato-Venereologica, 104, adv40645. https://doi.org/10.2340/actadv.v104.40645.

https://creativecommons.org/licenses/by-nc/4.0/
2024 © Author(s). Published by MJS Publishing, on behalf of the Society for Publication of Acta Dermato-Venereologica. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/).
https://creativecommons.org/licenses/by-nc/4.0/
doi:https://doi.org/10.2340/actadv.v104.40645
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:oulu-202409065720
Tiivistelmä
Abstract

The use of dipeptidyl peptidase-4 inhibitors (gliptins) to treat type 2 diabetes (T2DM) is associated with an in-creased risk of bullous pemphigoid (BP) (1). It is unclear whether prior gliptin use affects the clinical features or prognosis of BP. This retrospective study was designed to analyse the differences in characteristics and mortality between “regular” BP (rBP) and gliptin-associated BP (GABP).
Kokoelmat
https://creativecommons.org/licenses/by-nc/4.0/
Ellei muuten mainita, aineiston lisenssi on https://creativecommons.org/licenses/by-nc/4.0/